JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Loufrani, L.
Right arrow Articles by Levy, B. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Loufrani, L.
Right arrow Articles by Levy, B. I.

Vol. 291, Issue 2, 583-588, November 1999

Functional Evidence for an Angiotensin IV Receptor in Rat Resistance Arteries1

Laurent Loufrani, Daniel Henrion, Dominique Chansel, Raymond Ardaillou and Bernard I. Levy

Institut National de la Santé et de la Recherche Médicale U 141 and Institut Fédératif de Recherche Circulation-Lariboisière, Université Paris VII, Hôpital Lariboisière, Paris, France

To distinguish between the different effects of angiotensin IV (Ang IV) on resistance artery vasoreactivity, freshly isolated rat mesenteric arteries were perfused and the changes in their diameter were recorded under various conditions. Ang IV exerted vasoconstrictor effects on both normal vessels and vessels that had been precontracted with phenylephrine or serotonin. This effect was abolished by losartan or candesartan cilexetil, two type 1 angiotensin receptor antagonists, but not by PD 123319, a type 2 angiotensin receptor antagonist. No tachyphylaxis was observed for the vasoconstrictor effect of Ang IV. NG-nitro-L-arginine methyl ester, a nitric oxide synthase inhibitor, had no effect on Ang IV-induced vasoconstriction, whereas indomethacin, a cyclooxygenase inhibitor that was inactive by itself, influenced Ang IV-induced vasoconstriction, suggesting that Ang IV could stimulate the release of prostaglandins. Treatment of preconstricted vessels by candesartan cilexetil unraveled a vasodilator effect of Ang IV that was abolished by PD 123319, a type 2 angiotensin receptor antagonist. Unexpectedly, Ang IV still produced a vasoconstrictor effect on normal or preconstricted vessels after blockade of both type 1 and type 2 angiotensin receptors. Taken together, these results show that Ang IV influences resistance artery vasoreactivity via different mechanisms, one of which implicates a functionally active type 4 angiotensin receptor.

0022-3565/99/2912-0583$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
E.J. Belin de Chantemele, K. Retailleau, F. Pinaud, E. Vessieres, A. Bocquet, A.L. Guihot, B. Lemaire, V. Domenga, C. Baufreton, L. Loufrani, et al.
Notch3 Is a Major Regulator of Vascular Tone in Cerebral and Tail Resistance Arteries
Arterioscler. Thromb. Vasc. Biol., December 1, 2008; 28(12): 2216 - 2224.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
A. Vinh, R. E. Widdop, G. R. Drummond, and T. A. Gaspari
Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice
Cardiovasc Res, January 1, 2008; 77(1): 178 - 187.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
X. C. Li, D. J. Campbell, M. Ohishi, S. Yuan, and J. L. Zhuo
AT1 receptor-activated signaling mediates angiotensin IV-induced renal cortical vasoconstriction in rats
Am J Physiol Renal Physiol, May 1, 2006; 290(5): F1024 - F1033.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
V. Esteban, M. Ruperez, E. Sanchez-Lopez, J. Rodriguez-Vita, O. Lorenzo, H. Demaegdt, P. Vanderheyden, J. Egido, and M. Ruiz-Ortega
Angiotensin IV Activates the Nuclear Transcription Factor-{kappa}B and Related Proinflammatory Genes in Vascular Smooth Muscle Cells
Circ. Res., May 13, 2005; 96(9): 965 - 973.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
Y. D. Li, E. R. Block, and J. M. Patel
Activation of multiple signaling modules is critical in angiotensin IV-induced lung endothelial cell proliferation
Am J Physiol Lung Cell Mol Physiol, October 1, 2002; 283(4): L707 - L716.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
W. F. van Rodijnen, T. A. van Lambalgen, M. H. van Wijhe, G.-J. Tangelder, and P. M. ter Wee
Renal microvascular actions of angiotensin II fragments
Am J Physiol Renal Physiol, July 1, 2002; 283(1): F86 - F92.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
D. Henrion, N. Kubis, and B. I. Levy
Physiological and Pathophysiological Functions of the AT2 Subtype Receptor of Angiotensin II: From Large Arteries to the Microcirculation
Hypertension, November 1, 2001; 38(5): 1150 - 1157.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. Chen, J. M. Patel, and E. R. Block
Angiotensin IV-mediated pulmonary artery vasorelaxation is due to endothelial intracellular calcium release
Am J Physiol Lung Cell Mol Physiol, November 1, 2000; 279(5): L849 - L856.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.